Brokerages Expect Provention Bio Inc (NASDAQ:PRVB) to Announce -$0.31 EPS

Equities analysts expect Provention Bio Inc (NASDAQ:PRVB) to announce ($0.31) earnings per share for the current quarter, according to Zacks. Zero analysts have made estimates for Provention Bio’s earnings, with the highest EPS estimate coming in at ($0.30) and the lowest estimate coming in at ($0.31). Provention Bio reported earnings per share of ($1.05) in the same quarter last year, which indicates a positive year over year growth rate of 70.5%. The business is scheduled to announce its next quarterly earnings results on Monday, August 12th.

According to Zacks, analysts expect that Provention Bio will report full-year earnings of ($1.19) per share for the current financial year, with EPS estimates ranging from ($1.22) to ($1.15). For the next fiscal year, analysts expect that the company will report earnings of ($1.12) per share, with EPS estimates ranging from ($1.23) to ($1.02). Zacks’ EPS calculations are a mean average based on a survey of research firms that cover Provention Bio.

Provention Bio (NASDAQ:PRVB) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.11).

Several analysts have recently commented on PRVB shares. Chardan Capital started coverage on shares of Provention Bio in a research report on Monday, June 10th. They set a “buy” rating and a $20.00 price objective for the company. Zacks Investment Research downgraded shares of G1 Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, May 16th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of ACASTI PHARM-TS in a research report on Wednesday, June 26th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $12.19.

In other Provention Bio news, Director Anthony Digiandomenico purchased 25,000 shares of Provention Bio stock in a transaction that occurred on Monday, June 17th. The stock was acquired at an average price of $12.16 per share, with a total value of $304,000.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Ashleigh Palmer purchased 4,000 shares of Provention Bio stock in a transaction that occurred on Tuesday, June 18th. The stock was acquired at an average cost of $10.83 per share, with a total value of $43,320.00. The disclosure for this purchase can be found here. In the last three months, insiders purchased 39,000 shares of company stock valued at $456,920. 19.60% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of PRVB. Alambic Investment Management L.P. bought a new position in Provention Bio during the 4th quarter valued at $29,000. BlackRock Inc. lifted its stake in Provention Bio by 26.4% during the 4th quarter. BlackRock Inc. now owns 26,235 shares of the company’s stock valued at $46,000 after acquiring an additional 5,472 shares in the last quarter. Silverleafe Capital Partners LLC bought a new position in Provention Bio during the 1st quarter valued at $46,000. Finally, Lido Advisors LLC bought a new position in Provention Bio during the 4th quarter valued at $47,000. 1.77% of the stock is owned by institutional investors and hedge funds.

Shares of PRVB stock traded up $0.73 during trading hours on Friday, hitting $12.00. 292,729 shares of the company were exchanged, compared to its average volume of 552,451. The stock has a market capitalization of $448.32 million and a price-to-earnings ratio of -10.08. Provention Bio has a fifty-two week low of $1.52 and a fifty-two week high of $22.82. The company’s 50 day simple moving average is $9.22.

About Provention Bio

Provention Bio, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, oral CSF-1R inhibitor, which is in Phase 2a clinical trial for the treatment of Crohn's disease; PRV-300, anti-TLR3 mAb, which is in Phase 1b clinical trial for the treatment of ulcerative colitis; PRV-3279 for the treatment of lupus; and PRV-101, a multivalent coxsackie virus vaccine for the prevention of acute Coxsackie Virus B Vaccine and the prevention of the onset of T1D.

Recommended Story: Using the New Google Finance Tool

Get a free copy of the Zacks research report on Provention Bio (PRVB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Provention Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Provention Bio and related companies with MarketBeat.com's FREE daily email newsletter.